Analysis Group Researchers’ Study on Venous Thromboembolism Published in “Journal of Managed Care Pharmacy”
June 27, 2012
The Journal of Managed Care Pharmacy recently published an article on the economic impacts of venous thromboembolism (VTE) coauthored by professionals from Analysis Group’s Health Care Consulting practice and researchers from the University of Illinois at Chicago, Janssen Scientific Affairs LLC, and Henry Ford Hospital.
The paper “All-Cause and Potentially Disease-Related Health Care Costs Associated with Venous Thromboembolism in Commercial, Medicare, and Medicaid Beneficiaries” (June 2012, Vol. 18, Issue 5) outlines the results of a study designed to quantify the health care costs and clinical outcomes associated with the occurrence of an initial episode of VTE and its subsequent complications, such as recurrent VTE and post-thrombotic syndrome. These clotting conditions can obstruct blood flow and manifest as chronic pain and swelling.
The Analysis Group team, which included Vice President Patrick Lefebvre, Senior Economist François Laliberté, Economist Katherine Dea, and Managing Principal and Chief Epidemiologist Mei Sheng Duh, collaborated with external researchers to conduct this large matched-cohort study.
Their findings showed that patients with VTE were associated with a 3.6% risk of experiencing a hospital-documented recurrence of VTE and a 7.1% risk of experiencing a post-thrombotic syndrome event up to one year after the initial VTE episode. VTE was also associated with a significant health care cost burden: $15,941 per patient, per year, on average.
Read the article